Treatment of HEY and TOV21G cell lines with paclitaxel, momelotinib or a combination of both

Ovarian cancer HEY and TOV21G cell lines were treated with paclitaxel at a concentration at which 50% growth inhibition (GI₅₀) was obtained (0.05μg/mL for HEY cells and 0.01μg/mL for TOV21G cells). The response of HEY and TOV21G cell lines in response to paclitaxel was determined by MTT assay at 24 hour as described previously [35]. This was to ensure that the surviving cells had been exposed to an adequate concentration of the drug, while ensuring sufficient cell numbers for in vitro analyses. For momelotinib treatment, cells were screened for the response to different concentrations of momelotinib in both cell lines, and the concentration that gave optimum inhibition of P-JAK2 and P-STAT3 in response to paclitaxel was selected in both cell lines (1μM for both cell lines).